Profile Response Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

Molecular Profile CD274 positive
Therapy Atezolizumab
Indication/Tumor Type ovary epithelial cancer
Response Type predicted - sensitive


  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")


  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
CD274 positive ovary epithelial cancer predicted - sensitive Atezolizumab Case Reports/Case Series Actionable In a Phase I trial, Tecentriq (atezolizumab) treatment resulted in an objective response rate (ORR) of 22.2% (2/9, 1 complete response, 1 partial response) and a median progression-free survival of 2.9 months in patients with advanced or recurrent ovarian epithelial cancer, ORR was 25% (2/8) in patients with tumor CD274 (PD-L1) expression of 5% or higher and 0% (0/1) in patients with tumor CD274 (PD-L1) expression below 5% (PMID: 31204078; NCT01375842). 31204078
PubMed Id Reference Title Details
(31204078) Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers. Full reference...